Erratum: Hepatorenal syndrome: Are we missing some prognostic factors? (Digestive Diseases and Sciences DOI: 10.1007/s10620-011-1861-1);Hepatorenal syndrome: Are we missing some prognostic factors?

Digestive Diseases and Sciences

Volumn 57, Issue 1, 2012, Pages 210-214

  Martinez, Marco Olivera ^b   Sayles, Harlan ^a   Vivekanandan, Renuga ^b   D'Souza, Sharlene ^b   Florescu, Marius C ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Autoimmune hepatitis; Hemodialysis; Hepatorenal syndrome; Survival; Treatment

Indexed keywords

ALBUMIN; CREATININE; HYPERTENSIVE FACTOR; MIDODRINE; OCTREOTIDE; SODIUM;

ADULT; ARTICLE; AUTOIMMUNE HEPATITIS; CREATININE BLOOD LEVEL; END STAGE LIVER DISEASE; FEMALE; HEMODIALYSIS; HEPATORENAL SYNDROME; HUMAN; IDIOPATHIC DISEASE; KIDNEY FUNCTION; LIVER CANCER; MAJOR CLINICAL STUDY; MALE; MORTALITY; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SODIUM URINE LEVEL; SURVIVAL; SURVIVAL TIME; VIRUS HEPATITIS;

EID: 84856727091     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-011-1891-8     Document Type: Erratum

References (19)

1. F Salerno A Gerbes P Ginés F Wong V Arroyo 2007 Diagnosis prevention and treatment of the hepatorenal syndrome in cirrhosis: a consensus workshop of the international ascites club Gut 56 1310 1318 17389705 1:CAS:528:DC%2BD2sXhtVKgsbbJ (Pubitemid 47300435)
2. B Runyon 2009 Management of adult patients with ascites due to cirrhosis Hepatology 49 2087 2107 19475696 10.1002/hep.22853
3. A Gines A Escorsell P Gines, et al. 1993 Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites Gastroenterology 105 229 236 8514039 1:STN:280:DyaK3s3pt1yiug%3D%3D (Pubitemid 23234041)
4. V Arroyo P Gines AL Gerbes, et al. 1996 Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis Int Ascites Club Hepatol 23 164 176 1:STN:280:DyaK287jtlCmtQ%3D%3D (Pubitemid 26012105)
5. P Gines M Guevara V Arroyo J Rodes 2003 Hepatorenal syndrome Lancet 362 1819 1827 14654322 10.1016/S0140-6736(03)14903-3 1:CAS:528:DC%2BD3sXptlOiurg%3D (Pubitemid 37494763)
6. Wadei HM, Mai ML, Ahsan N, Gonwa TA. Hepatorenal syndrome: pathophysiology and management. Clin J Am Soc Nephrol. 2006;1:1066-1079. doi: 10.2215/CJN.01340406.
7. I Colle F Durand F Pessione E Rassiat J Bernuau E Barriere D Lebrec DC Valla R Moreau 2002 Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with Terlipressin: a retrospective analysis J Gastroenterol Hepatol 17 882 888 12164964 10.1046/j.1440-1746.2002.02816.x
8. K Watt J Uhanova GY Minuk 2002 Hepatorenal syndrome: diagnostic accuracy, clinical features, and outcome in a tertiary care center Am J Gastroenterol 97 2046 2050 12190175 10.1111/j.1572-0241.2002.05920.x
9. F Wong L Pantea K Sniderman 2004 Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome Hepatology 40 55 64 15239086 10.1002/hep.20262 1:CAS:528:DC%2BD2cXmtlSgtLc%3D (Pubitemid 38868923)
10. J Peron C Bureau L Gonzalez, et al. 2005 Treatment of hepatorenal syndrome as defined by the International Ascites Club by albumin and furosemide infusion according to the central venous pressure: a prospective pilot study Am J Gastroenterol 100 2702 2707 16393223 10.1111/j.1572-0241.2005.00271.x 1:CAS:528:DC%2BD28XmvFehtw%3D%3D
11. JF Platt JH Ellis JM Rubin RM Merion MR Lucey 1994 Renal duplex Doppler ultrasonography: a noninvasive predictor of kidney dysfunction and hepatorenal failure in liver disease Hepatology 20 362 369 8045497 10.1002/hep.1840200215 1:STN:280:DyaK2czitVyktw%3D%3D (Pubitemid 24233362)
12. K Lenz 2005 Hepatorenal syndrome: is it central hypovolemia, a cardiac disease, or part of gradually developing multiorgan dysfunction? Hepatology 42 263 265 16025501 10.1002/hep.20832 (Pubitemid 41061076)
13. C Skagen M Einstein MR Lucey A Said 2009 Combination treatment with octreotide, midodrine and albumin improves survival in patients with type 1 and type 2 hepatorenal syndrome J Clin Gastroenterol 43 680 685 19238094 10.1097/MCG.0b013e318188947c 1:CAS:528:DC%2BD1MXovVSnsrk%3D
14. F Keller H Heinze F Jochimsen J Passfall D Schuppan P Buttner 1995 Risk factors and outcome of 107 patients with decompensated liver disease and acute renal failure (including 26 patients with hepatorenal syndrome): the role of hemodialysis Ren Fail 17 135 146 7644764 10.3109/08860229509026250 1:STN:280:DyaK2Mznt1Kmtg%3D%3D
15. RK Capling B Bastani 2004 The clinical course of patients with type 1 hepatorenal syndrome maintained on hemodialysis Ren Fail 26 563 568 15526916 10.1081/JDI-200035988 (Pubitemid 39363289)
16. B Appenrodt J Zielinski KA Brensing J Heller T Sauerbruch M Schepke 2009 Degree of hepatic dysfunction and improvement of renal function predict survival in patients with HRS type I: a retrospective analysis Eur J Gastroenterol Hepatol 21 1428 1432 19794309 10.1097/MEG.0b013e32832ec16a
17. O Witzke M Baumann D Patschan S Patschan A Mitchell U Treichel G Gerken T Philipp A Kribben 2004 Which patients benefit from hemodialysis therapy in hepatorenal syndrome? J Gastroenterol Hepatol 19 1369 1373 15610310 10.1111/j.1440-1746.2004.03471.x (Pubitemid 40052855)
18. R Moreau F Durand T Poynard C Duhamel P Jean P Ichai, et al. 2002 Terlipressin in patients with cirrhosis and type I hepatorenal syndrome: a retrospective multicentric study Gastroenterology 122 923 930 11910344 10.1053/gast.2002.32364 1:CAS:528:DC%2BD38XjtFOmur8%3D (Pubitemid 34267275)
19. A Krag S Møller JH Henriksen NH Holstein-Rathlou FS Larsen F Bendtsen 2007 Terlipressin improves renal function in patients with cirrhosis and ascites without hepatorenal syndrome Hepatology 46 1863 1871 18027874 10.1002/hep.21901 1:CAS:528:DC%2BD2sXhsVGiur%2FF